Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Similar documents
Know Your Number Aggregate Report Single Analysis Compared to National Averages

MOLINA HEALTHCARE OF CALIFORNIA

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Total risk management of Cardiovascular diseases Nobuhiro Yamada

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

Risk Factors for Heart Disease

Depok-Indonesia STEPS Survey 2003

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Hospital Authority Convention 2010 Presented by : Dr Cheng Ming Kin Medical Officer,Department of Medicine Tseung Kwan O Hospital

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

WIN QUARTERLY UTILIZATION REPORT 7/1/2010 TO 12/31/2010. EXPERTISE PARTNERSHIP V A L U E April 20, 2011

Cardiovascular Risk Assessment and Management Making a Difference

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Section 03: Pre Exercise Evaluations and Risk Factor Assessment

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Obesity Prevention and Control: Provider Education with Patient Intervention

CVD Prevention, Who to Consider

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers

Normal cholesterol levels for men over 50

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

By: Dr Mehrnoosh Shanaki

SITA 100 mg (n = 378)

Development of the Automated Diagnosis CT Screening System for Visceral Obesity

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Client Report Screening Program Results For: Missouri Western State University October 28, 2013

Clinical Study Synopsis

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Treadmill Workstations: A Worksite Physical Activity Intervention

Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

Prevalence of cardiovascular disease risk factors in people of Asian Indian origin: Age and sex variation

The role of physical activity in the prevention and management of hypertension and obesity

WIN UTILIZATION REPORT 7/1/2010 TO 6/30/2011

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Why Screen at 23? What can YOU do?

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

The Potential for High-Intensity Interval Training to Reduce Cardiometabolic Disease Risk

CARDIOVASCULAR RISK FACTORS IN WHITE COLLAR WORKERS UNDER SHIFT WORK. K. Vangelova. National Center of Public Health and Analyses Sofia, Bulgaria

Supplementary Online Content

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

A study of waist hip ratio in identifying cardiovascular risk factors at Government Dharmapuri College Hospital

High Blood Cholesterol What you need to know

CARDIOVASCULAR HEALTH

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

5/28/2010. Pre Test Question

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Metabolic Syndrome and Workplace Outcome

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Review of guidelines for management of dyslipidemia in diabetic patients

Lipid Profiles. Important: Read over the section on correlation coefficients in the Guidelines for Statistics and Graphs in General Education Biology.

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Population: All participants Number of Obs: Variable # Sas Name: Sas Label: Categories: Variable # Sas Name: F80VNUM. Sas Label: Categories:

NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet

Frequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya

Integrated Health/Person Centered Health Home Austin Travis County Integral Care

TODAY S ALLIANCE MEETING

Page 1. Disclosures. Background. No disclosures

Case Study: Chris Arden. Peripheral Arterial Disease

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea

An Overview on Cardiovascular Risks Definitions by Using Survival Analysis Techniques-Tehran Lipid and Glucose Study: 13-Year Follow-Up Outcomes

290 Biomed Environ Sci, 2016; 29(4):

CHAPTER IV RESEARCH METHOD. This study belongs to the field of Internal Medicine, specifically the field

Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes

Associations Between Lipid Measures and Metabolic Syndrome, Insulin Resistance and Adiponectin

CHAPTER 3 DIABETES MELLITUS, OBESITY, HYPERTENSION AND DYSLIPIDEMIA IN ADULT CENTRAL KERALA POPULATION

Planned Interventions

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

Report Operation Heart to Heart

Cardiovascular Disease Risk Behaviors of Nursing Students in Nursing School

BODYSTAT BODY COMPOSITION AND WELLNESS PROFILE FOR. Sample Report

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:

Introduction to results on Seasonal Changes in Cholesterol

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Healthy Firefighters USA Program

Positive Change for Life

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

Supplementary Appendix

Cardiovascular Complications of Diabetes

PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS

EFFICIENCY AND COST-EFFECTIVENESS OF DYSLIPIDEMIA SCREENING METHODS AMONG WORKERS IN BANGKOK

2013 Hypertension Measure Group Patient Visit Form

Supplementary Online Content

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Transcription:

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG); D: high-density lipoprotein cholesterol (HDL-C). *P<0.05; ***P<0.001, Student's t-test. ns: not significant.

Figure S2. Comparison of fasting plasma lipoprotein levels between different age groups of study participants (G1: 14 22, G2: 23 31, G3: 32 40, G4:41 49, G5: 50 58, and G5: 59 years). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG), D: high-density lipoprotein cholesterol (HDL-C). **P<0.01; ***P<0.001, Student's t-test. ns: not significant.

Figure S3. Age trends of medians in study population for A, TC (total cholesterol); LDL-C (low-density lipoprotein cholesterol); HDL-C (high-density lipoprotein cholesterol), and B, TG (triglycerides) in males and females.

Figure S4. Comparison of fasting plasma lipoprotein levels between urban and rural groups. Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG); D: high-density lipoprotein cholesterol (HDL-C). ns: not significant (P>0.05, Student's t-test).

Figure S5. Distribution of fasting plasma lipoprotein levels between white-collar and bluecollar groups of study population. Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG); D: highdensity lipoprotein cholesterol (HDL-C). ns: not significant (P>0.05, Student's t-test).

Figure S6. Comparison of fasting plasma lipoprotein levels between urban white-collar and urban blue-collar sub-groups of participants. Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG); D: high-density lipoprotein cholesterol (HDL-C). ns: not significant (P>0.05, Student's t-test).

Figure S7. Comparison of fasting plasma lipoprotein levels between smokers and nonsmokers sub-groups of study population. Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein cholesterol (LDL-C); C: triglycerides (TG); D: high-density lipoprotein cholesterol (HDL-C). P>0.05, Student's t-test. ns: not significant.

Figure S8. Effect of smoking status on stratification of the study population into plasma lipoprotein-based CHD-risk categories. Statistical significance was determined by z-test for two population proportions. (P>0.05).

Table S1. Clinical and metabolic characteristics of the study population. Parameter Mean ± SD Range Age (years) 35.90 ± 16.12 14 85 Weight (kg) 63.58 ± 13.68 35 102 Height (cm) 164.19 ± 8.36 142.24 187.96 BMI (kg/m 2 ) 23.59 ± 4.82 13.67 38.71 BMR (cal/day) 1387.12 ± 200.98 918 1953 Body Fat (%) 31.16 ± 7.89 15.89 54.54 Total body fat mass (kg) 20.68 ± 9.08 5.62 51.11 Waist circumference (cm) 85.77 ± 14.92 55.88 190.50 Wrist (cm) 16.61 ± 1.80 12.70 22.86 Waist-to-hip ratio 0.87 ± 0.12 0.58 2.03 Waist-to-height ratio 0.52 ± 0.09 0.37 1.14 Systolic BP (mmhg) 120.66 ± 20.16 61 224 Diastolic BP (mmhg) 77.34 ± 12.43 40 120 Fasting glucose (mg/dl) n=216 91.20 ± 38.21 22.69 289 TC (mg/dl) 162.18 ± 52.58 56 379 LDL-C (mg/dl) 93.87 ± 51.83 1 297 HDL-C (mg/dl) 44.57 ± 16.69 12 102 VLDL-C (mg/dl) 23.74 ± 9.60 4 72 TG (mg/dl) 140.60 ± 89.04 13 631 Non-HDL-C (mg/dl) 117.61 ± 55.42 17 344 TC/HDL-C 4.26 ± 2.47 1.27 15.97 TG/HDL-C 3.75 ± 2.88 0.21 19.34 LDL/HDL-C 2.62 ± 2.16 0.01 12.96 Non-HDL/HDL-C 3.26 ± 2.47 0.27 14.97 Male:Female ratio 54:65 Smokers (%) 12.6 Data are reported as means±sd except for smokers' percentage and male:female ratio. TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: highdensity lipoprotein cholesterol; BMI: body mass index; BMR: basal metabolic rate; BP: blood pressure.

Table S2. Clinical and metabolic characteristics of the male participants. Parameter Mean ± SD Range Age (years) 40.77 ± 16.65 15 85 Weight (kg) 68.76 ± 12.91 41 102 Height (cm) 170.13 ± 6.68 152.40 187.96 BMI, kg/m 2 23.79 ± 4.48 14.78 38.71 BMR (cal/day) 1530.59 ± 172.62 1159.25 1953.00 Body fat (%) 32.52 ± 7.08 17.53 53.24 Total body fat mass (kg) 23.05 ± 8.65 7.60 51.11 Waist circumference (cm) 90.56 ±14.74 63.50 190.50 Wrist (cm) 17.52 ± 1.32 14.73 20.32 Waist-to-hip ratio 0.92 ± 0.13 0.74 2.03 Waist-to-height ratio 0.53 ± 0.09 0.4 1.14 Systolic BP (mmhg) 123.88 ± 17.87 90 199 Diastolic BP (mmhg) 78.93 ± 12.78 40 120 Fasting glucose (mg/dl) n=95 89.21 ± 33.29 23 285 TC (mg/dl) 159.80 ± 53.28 61 379 LDL-C (mg/dl) 91.52 ± 50.78 1 297 HDL-C (mg/dl) 42.02 ± 16.63 12 97 VLDL-C (mg/dl) 26.27 ± 10.11 11 68 TG (mg/dl) 165.30 ± 94.94 38 511 Non-HDL-C (mg/dl) 117.79 ± 55.68 20 348 TC/HDL-C 4.46 ± 2.47 1.31 14.85 TG/HDL-C 4.56 ± 2.98 0.47 13.90 LDL/HDL-C 2.72 ± 2.15 0.01 11.56 Non-HDL/HDL-C 3.46 ± 2.47 0.31 13.85 Smokers (%) 27.78 Data are reported as means±sd except smokers' percentage. TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; BMI: body mass index; BMR: basal metabolic rate; BP: blood pressure.

Table S3. Clinical and metabolic characteristics of the female participants. Parameter Mean ± SD Range Age (years) 31.85 ± 14.47 14 75 Weight (kg) 59.20 ± 12.77 35 93 Height (cm) 159.26 ± 6.11 142.24 175.26 BMI, kg/m 2 23.42 ± 5.08 13.67 37.50 BMR (cal/day) 1267.93 ± 133.75 918 1709.38 Body fat (%) 18.71 ± 8.96 15.89 54.54 Total body fat mass (kg) 30.03 ± 8.33 5.62 49.08 Waist circumference (cm) 81.80 ± 13.87 55.88 119.38 Wrist (cm) 15.86 ± 1.80 12.70 22.86 Waist-to-hip ratio 0.82 ± 0.08 0.58 1.07 Waist-to-height ratio 0.51 ± 0.09 0.37 0.77 Systolic BP (mmhg) 117.99 ± 21.52 61 224 Diastolic BP (mmhg) 76.02 ± 11.98 43 114 Fasting glucose (mg/dl) n=121 92.75 ± 41.60 44.49 289 TC (mg/dl) 164.16 ± 51.90 56 355 LDL-C (mg/dl) 95.82 ± 52.61 3 268 HDL-C (mg/dl) 46.69 ± 16.44 13 102 VLDL-C (mg/dl) 21.64 ± 8.61 4 72 TG (mg/dl) 120.08 ± 78.09 13 631 Non-HDL-C (mg/dl) 117.46 ± 55.02 17 295 TC/HDL-C 4.09 ± 2.46 1.27 15.97 TG/HDL-C 3.07 ± 2.61 0.21 19.34 LDL/HDL-C 2.53 ± 2.17 0.08 12.96 Non-HDL/HDL-C 3.09 ± 2.46 0.27 14.97 Smokers (%) 0 Data are reported as means±sd except smokers' percentage. TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; BMI: body mass index; BMR: basal metabolic rate; BP: blood pressure.

Table S4. Classification of the study population into different occupational classes. Occupational Groups No. of Participants White collar Managers 4 Professionals 5 Technicians and associate professionals 7 Clerical support workers 6 Service and sales workers 2 Students* 196 Blue collar Skilled agricultural, forestry and fishery workers 36 Craft and related trades workers 8 Plant and machine operators, and Assemblers 10 Elementary occupations 15 Armed forces occupations 4 *Students were classified as white-collar participants. Table S5. Effect of gender on stratification of the study population into plasma lipoproteinbased coronary heart disease (CHD) risk-categories. Plasma lipoprotein Plasma lipoprotein CHD risk category Population % (n) P value Males (n=108) Females (n=130) Cholesterol Desirable 79.36 (86) 79.23 (103) 0.9362 Borderline high 12.96 (14) 11.54 (15) 0.7414 High 7.41 (8) 9.23 (12) 0.61708 LDL-C Optimal 61.11 (66) 58.46 (76) 0.6818 Near optimal/above optimal 16.67 (18) 18.46 (24) 0.71884 Borderline high 14.8 (16) 13.08 (17) 0.6965 High 4.63 (5) 3.08 (4) 0.5287 Very High 2.8 (3) 6.92 (9) 0.1443 HDL-C Low 47.22 (51) 33.08 (43) 0.02642* Average 38.89 (42) 50.77 (66) 0.06724 High 13.89 (15) 16.15 (21) 0.62414 TG Normal 54.63 (59) 79.23 (103) 0.0* Borderline high 19.44 (21) 12.31 (16) 0.13104 High 25 (27) 7.69 (10) 0.00024* Very High 0.93 (1) 0.77 (1) 0.8966 Data are reported as percent (n). *P<0.05, z-test for 2 population proportions. LDL-C: lowdensity lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.

Table S6. Effect of age on stratification of the study population into plasma lipoprotein-based coronary heart disease (CHD) risk-categories. Plasma Plasma lipoprotein Population % (n) lipoprotein CHD risk category G1 (n=71) G2 (n=47) G3 (n=29) G4 (n=39) G5 (n=26) G6 (n=26) Cholesterol Desirable 87.32 (62) 82.98 (39) 68.96 (20) 69.23 (27) 73.08 (19) 84.61 (22) Borderline high 4.22 (3) 10.64 (5) 13.79 (4) 23.08 (9) 19.23 (5) 11.54 (3) High 8.45 (6) 6.39 (3) 17.24 (5) 7.69 (3) 7.69 (2) 3.85 (1) LDL- C Optimal 69.01 (49) 72.34 (34)* 31.03 (9) 51.28 (20) 42.31(11)* 73.08 (19) Near optimal/above 16.9 (12) 8.51 (4) 24.14 (7) 20.51 (8) 34.62 (9)* 11.54 (3) optimal Borderline high 4.23 (3) 10.64 (5)* 31.03(9) 20.51 (8) 15.38 (4) 11.54 (3) High 4.22 (3) 4.25 (2) 3.45 (1) 5.13 (2) 0 (0) 3.85 (1) Very High 5.63 (4) 4.25 (2) 10.34 (3) 2.56 (1) 7.69 (2) 0 (0) HDL- C Low 36.62 (26) 29.79 (14)* 55.17 (16) 43.59 (17) 42.31 (11) 34.62 (9) Average 49.29 (35) 42.55 (20) 27.59 (8)* 53.85 (21) 38.46 (10) 57.69 (15) High 14.1 (10) 27.66 (13) 17.24 (5)* 2.56 (1)* 19.23 (5) 7.69 (2) TG Normal 87.32 (62) 76.56 (36) 68.96 (20) 51.28 (20) 46.15 (12) 46.15 (12) Borderline high 9.86 (7) 8.51 (4) 13.79 (4) 17.95 (7) 30.77 (8) 26.92 (7) High 2.82 (2)* 14.89 (7) 17.24 (5) 28.2 (11) 23.08 (6) 23.08 (6) Very High 0 (0) 0 (0) 0 (0) 2.56 (1) 0 (0) 3.85 (1) Age groups in years: G1 (14 22), G2 (23 31), G3 (32 40), G4 (41 49), G5 (50 58), and G6 ( 59). *P<0.05, comparisons were made between the consecutive age groups (z-test for 2 population proportions). LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides. Table S7. Prevalence of various isolated and mixed dyslipidemias in the study population. Type of Dyslipidemia Percentage (proportion) At least one lipid-fraction affected 62.6 (149/238) Isolated dyslipidemia TC>200 0 (0/238) LDL-C 130 0.85 (2/238) HDL-C <40 17.23 (41/238) TG 150 11.8 (28/238) Mixed dyslipidemia TC>200, LDL-C 130 5.04 (12/238) TC>200, HDL-C <40 0 (0/238) TC>200, TG 150 2.1 (5/238) LDL-C 130, HDL-C <40 2.52 (6/238) LDL-C 130, TG 150 0 (0/238) TG 150, HDL-C <40 8.40 (20/238) TG 150, HDL-C <40, LDL-C 130 1.26 (3/238) HDL-C <40, LDL-C 130, TC>200 5.04 (12/238) HDL-C <40, TC>200, TG 150 0.42 (1/238) TG 150, LDL-C 130, TC>200 3.78 (9/238) HDL-C <40, LDL-C 130, TC>200, TG 150 4.20 (10/238) TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride.